NCT00212290View on ClinicalTrials.gov

Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

December 31, 2006

Conditions
Insulin ResistanceType 2 Diabetes Mellitus
Interventions
DRUG

pioglitazone

DRUG

nateglinide

DRUG

placebo

Trial Locations (2)

98108

VA Puget Sound Health Care System (Seattle Campus), Seattle

98493

VA Puget Sound Health Care System (American Lake Campus), Tacoma

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00212290 - Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes | Biotech Hunter | Biotech Hunter